These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29960950)

  • 1. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
    Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
    Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S; Reddy VA; Arora S; Patel K
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies.
    Ali ISM; Sajad UA; Abdul Rasool BK
    PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
    Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
    Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil loaded nanodelivery systems for improved oral bioavailability.
    Dudhipala N; Veerabrahma K
    Ther Deliv; 2017 Feb; 8(2):79-88. PubMed ID: 28088883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
    Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
    Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.
    Zhang Y; Che E; Zhang M; Sun B; Gao J; Han J; Song Y
    Int J Pharm; 2014 Oct; 473(1-2):375-83. PubMed ID: 25051114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
    Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
    Zhang Z; Gao F; Bu H; Xiao J; Li Y
    Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
    Ugurlu T; Nalbantoglu A; Sengel-Turk CT
    Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
    Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
    J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
    Shaikh SM; Avachat AM
    Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
    Surampalli G; Nanjwade BK; Patil PA; Chilla R
    Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations.
    Yuksel N; Bayindir ZS; Aksakal E; Ozcelikay AT
    Int J Biol Macromol; 2016 Jan; 82():453-63. PubMed ID: 26455402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
    Sezgin-Bayindir Z; Antep MN; Yuksel N
    AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs.
    Zhang L; Zhu W; Lin Q; Han J; Jiang L; Zhang Y
    Int J Nanomedicine; 2015; 10():3291-302. PubMed ID: 25995635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion.
    Yu F; He C; Waddad AY; Munyendo WL; Lv H; Zhou J; Zhang Q
    Drug Dev Ind Pharm; 2014 Jun; 40(6):774-82. PubMed ID: 23679668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Self-Nanoemulsifying Drug Delivery System for Enhancing the Oral Bioavailability of Candesartan Cilexetil: Ex Vivo and In Vivo Evaluation.
    AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
    J Pharm Sci; 2019 Nov; 108(11):3599-3608. PubMed ID: 31348934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
    Miao X; Sun C; Jiang T; Zheng L; Wang T; Wang S
    J Pharm Pharm Sci; 2011; 14(2):196-214. PubMed ID: 21733409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.